Despite progress in early detection and therapeutic strategies, breast cancer remains a leading cause of cancer-related death among women globally. Due to the heterogeneity and complex tumor biology, breast cancer patients with similar diagnoses might have different prognoses and responses to treatment. Metabolomics is the branch of “omics” technologies that involves high-throughput identification and quantification of small-molecule metabolites in the metabolome. Cancer cells must be able to convert nutrients to biomass while maintaining energy production, which requires reprogramming of central metabolic processes. This phenomenon is increasingly recognized as a potential target for treatment, but also as a source for biomarkers that can be used for prognosis, risk stratification, and therapy monitoring. This webinar will introduce NMR-based metabolomics research in breast cancer, covering aspects in the analytical pipeline to enable identification of prognostic and predictive biomarkers.
Important note: The methods and solutions discussed during the webinar are for research use only and not for use in clinical diagnostic procedures.
May 14, 2020
Dr. Tone Frost Bathen
Head Professor, MR Cancer Group
Dr. Charlie Carter
Editorial Team SelectScience